BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 35269800)

  • 1. Biomolecular and Genetic Prognostic Factors That Can Facilitate Fertility-Sparing Treatment (FST) Decision Making in Early Stage Endometrial Cancer (ES-EC): A Systematic Review.
    Tanos P; Dimitriou S; Gullo G; Tanos V
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproductive and Oncologic Outcomes in Young Women with Stage IA and Grade 2 Endometrial Carcinoma Undergoing Fertility-Sparing Treatment: A Systematic Review.
    Etrusco A; Laganà AS; Chiantera V; Mikuš M; Arsalan HM; d'Amati A; Vitagliano A; Cicinelli E; Favilli A; D'Amato A
    Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of prognosis and pregnancy outcomes of fertility-preserving treatment for patients with stage Ⅰa, grade 2 endometrial cancer].
    Wang YQ; Zhou R; Xu LJ; Xia M; Lu Q; Liu GL; Shen DH; Wang G; He M; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 May; 55(5):327-332. PubMed ID: 32464721
    [No Abstract]   [Full Text] [Related]  

  • 4. Fertility-Sparing Approach in Patients with Endometrioid Endometrial Cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
    Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
    Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia: Case series of 30 patients and systematic review.
    Piatek S; Michalski W; Sobiczewski P; Bidzinski M; Szewczyk G
    Eur J Obstet Gynecol Reprod Biol; 2021 Aug; 263():139-147. PubMed ID: 34214800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies.
    Bani MA; Maulard A; Morice P; Chargari C; Genestie C
    Anticancer Res; 2024 Feb; 44(2):445-452. PubMed ID: 38307584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
    De Marzi P; Bergamini A; Luchini S; Petrone M; Taccagni GL; Mangili G; Colombo G; Candiani M
    J Minim Invasive Gynecol; 2015; 22(7):1178-82. PubMed ID: 26092080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal duration of fertility-sparing hormonal treatment for early-stage endometrioid endometrial cancer.
    Shim SH; Chae SH; So KA; Lee SJ; Lee JY; Kim TJ; Han ES; Kang SB
    Gynecol Oncol; 2021 Jun; 161(3):810-816. PubMed ID: 33875233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of pregnancy outcome after fertility-preserving treatment among women with atypical endometrial hyperplasia or endometrial carcinoma].
    Xiao ZR; Lu Q; Zhou R; Wang YQ; Liang WY; Liu HX; Tang HR; Wu GZ; Liu XS; Zhang H; Ren Y; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2020 Dec; 55(12):857-864. PubMed ID: 33355761
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of a fertility-sparing re-treatment for recurrent atypical endometrial hyperplasia and endometrial cancer: a systematic literature review.
    Murakami I; Machida H; Morisada T; Terao Y; Tabata T; Mikami M; Hirashima Y; Kobayashi Y; Baba T; Nagase S
    J Gynecol Oncol; 2023 Jul; 34(4):e49. PubMed ID: 36929578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chances of pregnancy and live birth among women undergoing conservative management of early-stage endometrial cancer: a systematic review and meta-analysis.
    Herrera Cappelletti E; Humann J; Torrejón R; Gambadauro P
    Hum Reprod Update; 2022 Feb; 28(2):282-295. PubMed ID: 34935045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer.
    Chung YS; Woo HY; Lee JY; Park E; Nam EJ; Kim S; Kim SW; Kim YT
    Am J Obstet Gynecol; 2021 Apr; 224(4):370.e1-370.e13. PubMed ID: 33039397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia.
    Fan Y; Li X; Wang J; Wang Y; Tian L; Wang J
    Reprod Biol Endocrinol; 2021 Aug; 19(1):118. PubMed ID: 34344384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis.
    Koskas M; Uzan J; Luton D; Rouzier R; Daraï E
    Fertil Steril; 2014 Mar; 101(3):785-94. PubMed ID: 24388202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management.
    Vaugon M; Peigné M; Phelippeau J; Gonthier C; Koskas M
    Reprod Biomed Online; 2021 Sep; 43(3):495-502. PubMed ID: 34315696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma.
    Guillon S; Popescu N; Phelippeau J; Koskas M
    Int J Gynaecol Obstet; 2019 Sep; 146(3):277-288. PubMed ID: 31197826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
    Mitsuhashi A; Sato Y; Kiyokawa T; Koshizaka M; Hanaoka H; Shozu M
    Ann Oncol; 2016 Feb; 27(2):262-6. PubMed ID: 26578736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [GnRH-a combined fertility-sparing re-treatment in women with endometrial carcinoma or atypical endomertial hyperplasia who failed to oral progestin therapy].
    Chen JY; Cao DY; Zhou HM; Yu M; Yang JX; Wang JH; Zhang Y; Cheng NH; Peng P
    Zhonghua Fu Chan Ke Za Zhi; 2021 Aug; 56(8):561-568. PubMed ID: 34420288
    [No Abstract]   [Full Text] [Related]  

  • 19. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience.
    Wang Y; Yu M; Yang JX; Cao DY; Yuan Z; Zhou HM; Zhang Y; Li L; Shen K; Wu H
    Int J Clin Oncol; 2019 Jun; 24(6):712-720. PubMed ID: 30746595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical analysis of fertility-sparing therapy of patients with complex atypical hyperplasia and endometrial cancer].
    Morimoto C; Wang YQ; Zhou R; Wang JL
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):936-942. PubMed ID: 36241236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.